Welcome to our dedicated page for Celldex Therapeutics SEC filings (Ticker: CLDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Celldex Therapeutics, Inc. (NASDAQ: CLDX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Celldex is a biopharmaceutical company focused on antibody-based therapies in immunology, and its filings offer detailed information on clinical programs, financial position and material events affecting the business.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports for discussions of Celldex’s pipeline, including barzolvolimab in chronic spontaneous urticaria (CSU), cold urticaria (ColdU), symptomatic dermographism (SD), prurigo nodularis (PN) and atopic dermatitis (AD), as well as the bispecific antibody CDX-622. These reports typically describe the company’s focus on mast cell biology, key risk factors, research and development spending and overall operating results.
Form 8-K current reports capture material events such as clinical trial readouts and financial updates. Recent examples include 8-K filings referencing topline Phase 2 results for barzolvolimab in eosinophilic esophagitis (EoE) and quarterly financial results press releases. These documents help readers track how new data and business developments are communicated to regulators and the market.
Through Stock Titan, users can also access Section 16 filings such as Form 4, where available, to monitor insider transactions in CLDX common stock, and proxy-related filings that discuss governance and executive matters. AI-powered summaries on this page are designed to explain the key points of lengthy filings, highlight clinically and financially relevant sections, and make it easier to compare updates over time.
All filings are sourced directly from EDGAR and updated as new documents are submitted, giving investors, analysts and researchers a structured view of Celldex’s regulatory history and ongoing disclosure around its immunology-focused programs.
Celldex Therapeutics officer Freddy A. Jimenez reported selling 4,166 shares of Celldex Therapeutics, Inc. common stock on December 4, 2025 at $29.095 per share. Following this sale, he directly owns 30,796 shares. The report identifies him as the company’s Senior Vice President and General Counsel and indicates the Form 4 was filed for a single reporting person.
Celldex Therapeutics (CLDX) filed a Form 4 reporting option exercises and a share sale by an insider. On 11/13/2025, the reporting person exercised three incentive stock options for 6,876 shares at $9.0165, 26,672 shares at $10.38, and 15,750 shares at $22.48, receiving common stock in each case. On the same date, they sold 49,298 common shares at a weighted average price of $24.0005 per share, with trades executed between $24.00 and $24.05. After these transactions, the insider directly owned 20,833 common shares and held 7,875 derivative securities (options) directly.
Celldex Therapeutics (CLDX) reported a Form 4 for its SVP & Chief Commercial Officer, noting the grant of 100,000 stock options on 11/10/2025 under the company’s 2021 Omnibus Equity Incentive Plan at an exercise price of $22.67 per share. The options expire on 11/10/2035.
The filing states 25% of the award vests on 11/10/2026, with the remainder vesting in equal quarterly installments over the next 12 quarters. Following the grant, 100,000 derivative securities are listed as beneficially owned in direct form.
Celldex Therapeutics (CLDX) filed a Form 3, the initial statement of beneficial ownership for a company insider. The reporting person is Teri Lawver, who serves as SVP & Chief Commercial Officer. The filing states that no securities are beneficially owned by the reporting person.
The date of event is 11/10/2025, and the form was filed on an individual basis. The document was signed by /s/ Sam Martin, attorney-in-fact for Teri Lawver on 11/12/2025.
Celldex Therapeutics (CLDX) filed its Q3 2025 10-Q, reporting no revenue for the quarter and higher operating spend as clinical programs advanced. For the three months ended September 30, 2025, operating expenses were $73.6 million and the company recorded a net loss of $67.0 million (vs. $42.1 million a year ago). For the nine months, operating expenses were $201.6 million with a net loss of $177.4 million.
Liquidity remains strong: as of September 30, 2025, cash, cash equivalents and marketable securities totaled $583.2 million. Net cash used in operating activities was $147.0 million for the nine months. Management states these resources are expected to fund operations for at least the next twelve months from issuance. R&D spend is led by the barzolvolimab (anti‑KIT) program, which accounted for $133.97 million of R&D in the nine-month period; CDX‑622 and other programs accounted for the balance. An at‑the‑market facility with $300.0 million registered capacity remained unsold at quarter end. Common shares outstanding were 66,446,846 at September 30, 2025.
Celldex Therapeutics (CLDX) reported that it furnished a press release announcing its third‑quarter 2025 financial results. The company disclosed this under Item 2.02 and attached the full press release as Exhibit 99.1, which is incorporated by reference.
The company stated the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as expressly set forth by specific reference.
Celldex Therapeutics filed a Form 8-K to report that, on August 19, 2025, it issued a press release with results from its Phase 2 study of Barzolvolimab in Eosinophilic Esophagitis (EoE), a chronic inflammatory disease of the esophagus. The company attached this press release as Exhibit 99.1 and incorporated it by reference, making the clinical trial outcome an official part of its public disclosures.
Celldex Therapeutics insider sale disclosure: Freddy A. Jimenez, SVP & General Counsel and officer of Celldex Therapeutics, reported two open-market dispositions of common stock on 08/13/2025. He sold 341 shares at $23.9515 and 430 shares at $25.415. After these transactions he beneficially owned 34,962 shares. The filing notes 269 of the reported shares were acquired under the company’s 2004 Employee Stock Purchase Plan. The Form 4 was signed by an attorney-in-fact on 08/15/2025.
This Schedule 13G/A reports that Eventide Asset Management, LLC and two individuals, Finny Kuruvilla, M.D., Ph.D. and Robin C. John, each are associated with an aggregate beneficial ownership of 1,356,186 shares of Celldex Therapeutics common stock, representing 2.0% of the class. The filing cites the date of event requiring filing as 06/30/2025 and contains signatures dated 08/14/2025.
Eventide is reported with sole voting and sole dispositive power over 1,356,186 shares, while Kuruvilla and John are reported with shared voting and shared dispositive power over the same 1,356,186 shares. Item 5 explicitly states this is an ownership of 5 percent or less of a class.
The filing identifies Eventide as organized in Delaware and lists the filers' address as One International Place, Suite 4210, Boston, Massachusetts. The exhibit includes a joint filing agreement executed August 14, 2025, and Item 10 contains a certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.